Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares (NQ:KNSA)

78.45 -0.88 (-1.11%)
Streaming Delayed Price Updated: 11:29 AM EDT, Sep 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares

< Previous 1 2 3 4 5 6 Next >
News headline image
Examining the Future: Kiniksa Pharmaceuticals's Earnings Outlook ↗
 
Via Benzinga
News headline image
3 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now ↗
Via The Motley Fool
News headline image
Kiniksa Pharmaceuticals Stock Is Attractive From Valuation Perspective-JP Morgan Analyst ↗
Kiniksa shifts focus to cardiovascular indications, halts abiprubart in Sjögren's, ends its AstraZeneca deal, and advances KPL-387 for recurrent pericarditis. 
Via Benzinga
News headline image
Earnings Scheduled For February 25, 2025 ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Exploring Kiniksa Pharmaceuticals's Earnings Expectations ↗
 
Via Benzinga
News headline image
Earnings Outlook For Kiniksa Pharmaceuticals ↗
 
Via Benzinga
News headline image
Earnings Outlook For Kiniksa Pharmaceuticals ↗
 
Via Benzinga
News headline image
NHL Hall-of-Famer, Henrik Lundqvist, Teams Up with Kiniksa Pharmaceuticals to Launch Life DisRPted™ Campaign to Drive Awareness of Recurrent Pericarditis
– Life DisRPted is an educational campaign aimed at promoting early diagnosis and treatment of recurrent pericarditis, a painful and debilitating chronic autoinflammatory disease – 
From Kiniksa Pharmaceuticals, Ltd.
Via GlobeNewswire
News headline image
KNSA Stock Earnings: Kiniksa Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024 ↗
KNSA stock results show that Kiniksa Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Danaher Posts Upbeat Earnings, Joins Spotify, MSCI, Owens & Minor And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Why Comcast Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
 
Via Benzinga
Sector Spotlight: Orphan Drug Developers With Significant Upside
Via AB Newswire
Topics ETFs
Sector Spotlight: Orphan Drug Developers With Significant Upside
The biotech sector is finally beginning to recover following a two year stretch of underperformance that was largely driven by rising interest rates and other macro factors. Biotech has a track record... 
Via TheNewswire.com
Topics ETFs
News headline image
KNSA Stock Earnings: Kiniksa Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024 ↗
KNSA stock results show that Kiniksa Pharmaceuticals missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Why Longboard Pharmaceuticals Shares Are Trading Higher By Around 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Shares of Longboard Pharmaceuticals, Inc. 
Via Benzinga
News headline image
The 3 Most Undervalued Biotech Stocks to Buy in December ↗
Biotech is an increasing area of interest in the financial markets, line your portfolio up with these winning biotech stocks. 
Via InvestorPlace
News headline image
Earnings Scheduled For April 23, 2024 ↗
Companies Reporting Before The Bell • RTX (NYSE:RTX) is expected to report quarterly earnings at $1.23 per share on revenue of $18.41 billion. 
Via Benzinga
News headline image
7 Underappreciated Biotech Stocks to Pick Up on the Cheap ↗
With questions rising about the economy, investors may consider undervalued biotech stocks for their relative insulation factor. 
Via InvestorPlace
Topics Economy
News headline image
Amicus Therapeutics Stock Reaches 80+ Relative Strength Benchmark ↗
Amicus Therapeutics sees its Relative Strength Rating move into the 80-plus level. 
Via Investor's Business Daily
News headline image
5 Value Stocks In The Healthcare Sector ↗
 
Via Benzinga
News headline image
5 Value Stocks To Watch In The Healthcare Sector ↗
 
Via Benzinga
News headline image
Vertex Pharmaceuticals Stock Shows Rising Relative Strength, Hits 80+ ↗
Vertex Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 81. 
Via Investor's Business Daily
News headline image
ACELYRIN Stock Scores Relative Strength Rating Upgrade; Hits Key Threshold ↗
One key metric to look for in a stock is an 80-plus Relative Strength Rating. ACELYRIN stock hit that mark on Tuesday, with a jump to 81. 
Via Investor's Business Daily
News headline image
Axsome Therapeutics Stock Earns Relative Strength Rating Upgrade ↗
A Relative Strength Rating upgrade for Axsome Therapeutics shows improving technical performance. 
Via Investor's Business Daily
News headline image
Exelixis Stock Sees Rising Relative Strength Rating ↗
On Monday, Exelixis stock hit an key technical milestone, with its Relative Strength Rating rising to 87, an increase from 79 the day before. 
Via Investor's Business Daily
News headline image
Dynavax Technologies Stock Sees Renewed Technical Strength ↗
Dynavax Technologies shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 84. 
Via Investor's Business Daily
News headline image
Crude Oil Up 1%; Verizon Earnings Beat Views ↗
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 100 points on Tuesday. The Dow traded up 0.28% to 35,510.96 while the NASDAQ rose 0.91% to 14,187.05.... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Alaska Air Group Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Aurora Acquisition Corp. (NASDAQ: AURC) shares jumped 192% to $30.54. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.